Kayla Reid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kayla Reid has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Marco L. Davila
Roswell Park Comprehensive Cancer Center
44 shared publications - Andrea Hoeschen
Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota
24 shared publications - Anne A. Eaton
University of Minnesota
24 shared publications - Brian Christopher Betts
Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
24 shared publications - Bruce R. Blazar
University of Minnesota
24 shared publications - Connor Demorest
Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota
24 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Human CD83 cell surface tissue microarray (TMA)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Human CD83 cell surface tissue microarray (TMA)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Clinical outcomes based on chronic GVHD or frequency of circulating CD83 B cells or Tfh
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Clinical outcomes based on chronic GVHD or frequency of circulating CD83 B cells or Tfh
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Clinical outcomes based on grade II-IV acute GVHD or frequency of circulating CD83, CD4 T cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Clinical outcomes based on grade II-IV acute GVHD or frequency of circulating CD83, CD4 T cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Increased CD4 T cell CD83 expression is associated with earlier acute GVHD diagnosis
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Increased CD4 T cell CD83 expression is associated with earlier acute GVHD diagnosis
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
CD83 CAR T does not impair human hematopoiesis in vivo
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
CD83 CAR T does not impair human hematopoiesis in vivo
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Purpose:Acute and chronic GVHD remain major causes of transplant-related morbidity and mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). We have shown CD83 chimeric antigen receptor (CAR) T cells prevent GVHD and kill myeloid leukemia cell lines. In this pilot study, we investigate CD83 expression on GVHD effector cells, correlate these discoveries with clinical outcomes, and evaluate critical therapeutic implications for transplant recipients.Experimental Design:CD83 expression was evaluated among circulating CD4+ T cells, B-cell subsets, T follicular helper (Tfh) cells, and monocytes from patients with/without acute or chronic GVHD (n = 48 for each group), respectively. CD83 expression was correlated with survival, TRM, and relapse after alloHCT. Differential effects of GVHD therapies on CD83 expression was determined.Results:CD83 overexpression on CD4+ T cells correlates with reduced survival and increased TRM. Increased CD83+ B cells and Tfh cells, but not monocytes, are associated with poor posttransplant survival. CD83 CAR T eliminate autoreactive CD83+ B cells isolated from patients with chronic GVHD, without B-cell aplasia as observed with CD19 CAR T. We demonstrate robust CD83 antigen density on human acute myeloid leukemia (AML), and confirm potent antileukemic activity of CD83 CAR T in vivo, without observed myeloablation.Conclusions:CD83 is a promising diagnostic marker of GVHD and warrants further investigation as a therapeutic target of both GVHD and AML relapse after alloHCT.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Purpose:Acute and chronic GVHD remain major causes of transplant-related morbidity and mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). We have shown CD83 chimeric antigen receptor (CAR) T cells prevent GVHD and kill myeloid leukemia cell lines. In this pilot study, we investigate CD83 expression on GVHD effector cells, correlate these discoveries with clinical outcomes, and evaluate critical therapeutic implications for transplant recipients.Experimental Design:CD83 expression was evaluated among circulating CD4+ T cells, B-cell subsets, T follicular helper (Tfh) cells, and monocytes from patients with/without acute or chronic GVHD (n = 48 for each group), respectively. CD83 expression was correlated with survival, TRM, and relapse after alloHCT. Differential effects of GVHD therapies on CD83 expression was determined.Results:CD83 overexpression on CD4+ T cells correlates with reduced survival and increased TRM. Increased CD83+ B cells and Tfh cells, but not monocytes, are associated with poor posttransplant survival. CD83 CAR T eliminate autoreactive CD83+ B cells isolated from patients with chronic GVHD, without B-cell aplasia as observed with CD19 CAR T. We demonstrate robust CD83 antigen density on human acute myeloid leukemia (AML), and confirm potent antileukemic activity of CD83 CAR T in vivo, without observed myeloablation.Conclusions:CD83 is a promising diagnostic marker of GVHD and warrants further investigation as a therapeutic target of both GVHD and AML relapse after alloHCT.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Table S5 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S5 shows baseline patient and tumor characteristics in high risk patients
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S5 shows baseline patient and tumor characteristics in high risk patients
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S4: Baseline patient and tumor characteristics in the validation cohorts
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Table S4: Baseline patient and tumor characteristics in the validation cohorts